Oncternal Therapeutics, Inc. (ONCT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Based on dividend-adjusted daily data since Feb 6, 2026, ONCT's average daily return is 0.00%, while the average monthly return is 0.00%.

Historically, 20% of months were positive and 80% were negative. The best month was May 2026 with a return of 0.0%, while the worst month was Feb 2026 at 0.0%. The longest winning streak lasted 1 consecutive months, and the longest losing streak was 0 months.

On a daily basis, ONCT closed higher 1% of trading days. The best single day was May 7, 2026 with a return of 0.0%, while the worst single day was Feb 9, 2026 at 0.0%.

Oncternal Therapeutics, Inc. has an annualized alpha of 0.00%, beta of -0.00, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 09, 2026.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (0.00%) than losses (-0.00%) - typical of diversified or defensive assets.
• Beta of -0.00 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

The table below present risk-adjusted performance metrics for Oncternal Therapeutics, Inc. (ONCT) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Oncternal Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The portfolio has not yet recovered.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Oncternal Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Oncternal Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.